About: NIAID resources for developing new therapies for severe viral infections

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: NIAID resources for developing new therapies for severe viral infections Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	NIAID resources for developing new therapies for severe viral infections
Creator	Greenstone, Heather Laughlin, Catherine Peacock, Susan Spinelli, Beth Taylor, Katherine Tseng, Christopher
Source	Elsevier; Medline; PMC
abstract	Abstract Severe viral infections, including hemorrhagic fever and encephalitis, occur throughout the world, but are most prevalent in developing areas that are most vulnerable to infectious diseases. Some of these can also infect related species as illustrated by the threatened extinction of gorillas by Ebola infection in west and central Africa. There are no safe and effective treatments available for these serious infections. In addition to the logistical difficulties inherent in developing a drug for infections that are sporadic and occur mainly in the third world, there is the overwhelming barrier of no hope for return on investment to encourage the pharmaceutical industry to address these unmet medical needs. Therefore, the National Institute of Allergy and infectious Disease (NIAID) has developed and supported a variety of programs and resources to provide assistance and lower the barrier for those who undertake these difficult challenges. The primary programs relevant to the development of therapies for severe viral infections are described and three case studies illustrate how they have been used. In addition, contact information for accessing these resources is supplied.
has issue date	2008-04-30(xsd:dateTime)
bibo:doi	10.1016/j.antiviral.2007.10.006
bibo:pmid	18061283
has license	els-covid
sha1sum (hex)	93244303c6041ad53fcc59cc06a03cc51621edcc
schema:url	https://doi.org/10.1016/j.antiviral.2007.10.006
resource representing a document's title	NIAID resources for developing new therapies for severe viral infections
has PubMed Central identifier	PMC7132394
has PubMed identifier	18061283
schema:publication	Antiviral Research
resource representing a document's body	covid:93244303c6041ad53fcc59cc06a03cc51621edcc#body_text
is schema:about of	named entity 'west' named entity 'Some' named entity 'infection' named entity 'developing' named entity 'hemorrhagic fever' named entity 'severe' named entity 'NEW' named entity 'DRUG' named entity 'DEVELOPMENT' named entity 'CASE STUDIES' named entity 'TREATMENTS' named entity 'ADDRESS' named entity 'VARIETY' named entity 'HEMORRHAGIC FEVER' named entity 'AVAILABLE' named entity 'GORILLAS' named entity 'NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASE' named entity 'HAVE' named entity 'NIAID' named entity 'EXTINCTION' named entity 'LOWER' named entity 'DIFFICULTIES' named entity 'MEDICAL NEEDS' named entity 'SAFE' named entity 'UNMET' named entity 'PRIMARY' named entity 'DESCRIBED' named entity 'ACCESSING' named entity 'PUBLISHED' named entity 'INCLUDING' named entity 'TO PROVIDE' named entity 'WEST' named entity 'ENCEPHALITIS' named entity 'THESE' named entity 'PREVALENT' named entity 'AREAS' named entity 'DEVELOPING' named entity 'BUT' named entity 'CONTACT INFORMATION' named entity 'RELATED SPECIES' named entity 'VULNERABLE' named entity 'INVESTMENT' named entity 'INFECTIOUS DISEASES' named entity 'OCCUR' named entity 'RELEVANT' named entity 'RESOURCES' named entity 'THERAPIES' named entity 'SEVERE VIRAL INFECTIONS' named entity 'CENTRAL AFRICA' named entity 'WORLD' named entity 'BARRIER' named entity 'USED' named entity 'ADDITION' named entity 'INFECTION' named entity 'EBOLA' named entity 'SUPPORTED' named entity 'RESOURCES' named entity 'PROGRAMS' named entity 'ASSISTANCE' named entity 'RETURN' named entity 'SPORADIC' named entity 'SUPPLIED' named entity 'HOW' named entity 'DIFFICULT' named entity 'INFECTIONS' named entity 'HOPE' named entity 'EFFECTIVE' named entity 'SEVERE VIRAL INFECTIONS' named entity 'CHALLENGES' named entity 'PHARMACEUTICAL INDUSTRY' named entity 'THERAPIES' named entity 'INFECT' named entity 'DEVELOPING' named entity 'viral infections' named entity 'vulnerable' named entity 'investment'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software